U.S. Health and Human Services Secretary Robert F. Kennedy, Jr. announced plans to partially deregulate 14 injectable peptides, a move that could reshape how Americans access compounds like BPC-157 and Sermorelin. Kennedy shared his intentions on an episode of the Joe Rogan Experience podcast #2461 that aired on February 27, 2025.
At a glance
- RFK Jr. announced plans to move 14 injectable peptides from FDA class 2 back to class 1, restoring access through licensed compounding pharmacies.
- The 2023 reclassification to class 2 had pushed many users toward gray and black markets, raising serious purity and safety concerns.
- Industry voices predict the change will bring more clinical adoption, but also higher costs and a narrower supplier field.
- No formal regulatory action has been taken yet; the timeline for any official change remains unconfirmed.
Why the Classification Change Matters
The current situation traces back to 2023, when the FDA tightened restrictions on compounding pharmacies’ use of certain peptides, reclassifying them from class 1 to class 2. That shift effectively removed many peptides from the legal compounding supply chain, driving demand toward research peptide vendors operating in a legal gray zone.
Under the research peptide loophole, products are sold for laboratory purposes only. Injecting them is technically not permitted. Still, widespread consumer use has continued, with supply chains running through domestic, Chinese, and Indian manufacturers of inconsistent quality.
Kennedy told Rogan that he plans to reverse this. “My hope is that [these peptides are] going to get moved to a place where people have access from ethical suppliers,” he said. Moving peptides back to class 1 status would allow compounding pharmacies to legally formulate and dispense them again, something many clinicians have been waiting for.
What Industry Voices Are Saying
Jay Campbell, author, prominent voice in the U.S. peptide community, and co-founder of BioLongevity Labs, sees the potential reclassification as a turning point for clinical adoption.
“The class 2 designation has kept a lot of physicians and clinics on the sidelines,” Campbell told AllAboutPeptides.com. “Once that barrier comes down, you’re going to see a wave of practitioners who were already interested but needed regulatory cover to move forward. The peptide conversation is about to go very mainstream, very fast.”
Campbell also expects a second wave of regulatory action to follow, potentially restricting foreign-sourced raw materials. That could narrow the field of active vendors considerably and push prices higher, but would also raise the floor on product purity.
The Gray Market Problem
The demand for peptides has grown rapidly across wellness, biohacking, and clinical circles. Compounds used for gut healing, injury recovery, and anti-aging have attracted mainstream attention. But the absence of a legal domestic supply chain has left many consumers sourcing from unverified channels.
Kennedy acknowledged the problem directly on the podcast. “With the gray market, you have no idea [what you’re getting], and a lot of this stuff we’ve looked at is just very, very substandard,” he said.
Recent supplier closures have underscored just how fragile that ecosystem can be. A clearer regulatory framework could address the instability that has defined the space in recent years.
New Entrants Are Already Moving
Several companies appear to be preparing for a more open regulatory environment. Telehealth provider Wisp launched a “healthy aging vertical” that includes peptide prescriptions alongside NAD+ and glutathione. Supplement tracking app SuppCo has also signaled plans to add peptide tracking features for users navigating the space.
Whether or not the reclassification moves forward on Kennedy’s proposed timeline, the direction of travel seems clear. Demand is there. Clinical interest is rising. And more companies are betting that the regulatory picture is about to get considerably cleaner.
What Comes Next
RFK Jr.’s proposed reclassification would be the most significant regulatory shift the peptide space has seen in years. If it moves forward, compounding pharmacies would regain the legal footing to produce and dispense these compounds, likely drawing more clinicians into the fold and pushing gray market activity to the margins.
No formal rule change has been announced. Any action from the FDA would go through the standard regulatory process. For now, the market is watching.
💡PEPTIDE PICKS: MORE TO EXPLORE
- Thinking about stacking peptides once access improves? Start with our guide to the best peptide stacks for different health goals.
- Curious about a category beyond the well-known injectables? Learn what peptide bioregulators are and how they differ from conventional peptides.
- Want faster recovery from workouts? Learn about the best peptides for muscle growth and repair